Antipsychotic-Like Effect of Agomelatine in a Rodent Model

Amaç: Daha önce yapılmış çalışmalarda agomelatinin nörofizyolojik sistemler üzerine olan etkileri gösterilmiştir, ancak bazı psikoz modelleri üzerine olan etkisi net değildir. Bu çalışmada agomelatinin sıçanlarda oluşturulan stereotipik hareketleri üzerine olan etkilerini incelemeyi amaçladık. Yöntem: Çalışmamızda erkek sıçanlarda apomorfinle indüklenen stereotipik hareket skorlaması değerlendirildi. Bu çalışmaya 4 grup alındı (n=6), 1. Grup 20mg/kg melatonin, 2. Grup 40mg/kg melatonin, 3. Grup 1mg/kg klorpromazin, 4. Grup izotonik 1 mL/kg alacak grup olarak belirlendi. Belirtilen ajanlar i.p olarak uygulandıktan 1 saat sonra sıçanlara apomorfin (2mg/kg, s.c.) uygulanarak indükte stereotipi skorları ve lokomotor aktiviteler değerlendirildi.Bulgular: Sonuçlarımız göstermektedir ki agomelatin, lokomotor aktivite ve stereotipi skorlarını istatistiksel olarak anlamlı derecede azaltmaktadır, üstelik bu durum doz artışıyla belirginleşmektedir. Sonuç: Agomelatinin steriotipi ve lokomotor aktiviteler gibi psikotik belirtiler üzerine olumlu etkilerinin olabileceği düşünülebilir.

Bir kemirgen modelinde agomelatinin antipsikotik benzeri etkisi

Objective: Agomelatine is a naphthalene bioisostere of melatonin. Melatonin is involved in several neurophysiological systems; nevertheless, data about the relationship between melatonin and psychosis such as schizophrenia are limited and contradictory. In this study, we examined the antipsychotic-like effects of agomelatine in a rodent model.Method: In this study, we evaluated the effect of agomelatine on novelty-induced rearing behavior and apomorphine-induced stereotypical behavior in male rats. Agomelatine (20 and 40mg/kg, i.p.), chlorpromazine (1mg/kg, i.p.), or isotonic NaCl (1mL/kg, i.p.) were administered to four groups of rats (n=6), respectively. An hour later, apomorphine (2mg/kg, s.c.) was administered to each rat.Results: Our results showed that either dose of agomelatine decreased rearing behavior in rats significantly, in a dose dependent manner. Agomelatine also decreased the stereotypical behaviour scores like chlorpromazine did. Conclusion: We conclude that agomelatine has beneficial effects on rearing and stereotypical behaviour, which were accepted to be indicators of antipsychotic effect.

___

  • 1. Parlakpinar H, Sahna E, Ozer MK, Ozugurlu F, Vardi N, Acet A. Physiological and pharmacological concentrations of melatonin protect against cisplatin-induced acute renal injury. J Pineal Res 2002; 33:161-166.
  • 2. Maldonado MD, Reiter RJ, Pérez-San-Gregorio MA. Melatonin as a potential therapeutic agent in psychiatric illness. Hum Psychopharmacol 2009; 24:391-400.
  • 3. Mozaffari S, Abdollahi M. Melatonin, a promising supplement in inflammatory bowel disease: a comprehensive review of evidences. Curr Pharm Des 2011; 17:4372-4378.
  • 4. Esposito E, Paterniti I, Mazzon E, Bramanti P, Cuzzocrea S. Melatonin reduces hyperalgesia associated with inflammation. J Pineal Res 2010; 49:321-331.
  • 5. Karakas A, Coskun H, Kaya A, Kucuk A, Gunduz B. The effects of the intraamygdalar melatonin injections on the anxiety like behavior and the spatial memory performance in male Wistar rats. Behav Brain Res 2011; 222:141-150.
  • 6. Parlakpinar H, Ozer MK, Sahna E, Vardi N, Cigremis Y, Acet A. Amikacin induced acute renal injury in rats: protective role of melatonin. J Pineal Res 2003; 35:85-90.
  • 7. Reiter RJ, Tan DX, Pappolla MA. Melatonin relieves the neural oxidative burden that contributes to dementias. Ann N Y Acad Sci 2004; 1035:179-196.
  • 8. Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005; 27:119-130.
  • 9. Catena-Dell’Osso M, Marazziti D, Rotella F, Bellantuono C. Emerging targets for the pharmacological treatment of depression: focus on melatonergic system. Curr Med Chem 2012; 19:428-437.
  • 10. Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 2008; 29:445-453.
  • 11. Woolley DW, Shaw E. Some neurophysiological aspects of serotonin. Br Med J 1954; 2:122-126.
  • 12. Stoll WA. Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neurol Psychiatr 1947; 60:279-323.
  • 13. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47:27-38.
  • 14. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001; 156:117-154.
  • 15. Sandyk R, Kay SR. Pineal melatonin in schizophrenia: a review and hypothesis. Schizophr Bull 1990;16:653-662.
  • 16. Kay SR, Sandyk R. Experimental models of schizophrenia. Int J Neurosci 1991; 58:69-82.
  • 17. Fanget F, Claustrat B, Dalery J, Brun J, Terra JL, Marie-Cardine M, Guyotat J. Nocturnal plasma melatonin levels in schizophrenic patients. Biological Psychiatry 1989; 25:499-501.
  • 18. Bersani G, Mameli M, Garavini A, Pancheri P, Nordio M. Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia. Neuro Endocrinol Lett 2003; 24:181-184.
  • 19. Trbovic SM. Schizophrenia as a possible dysfunction of the suprachiasmatic nucleus. Med Hypotheses 2010; 74:127-131.
  • 20. Park HJ, Park JK, Kim SK, Cho AR, Kim JW, Yim SV, Chung JH. Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J Mol Neurosci 2011; 45:304-308.
  • 21. Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis 2012; 27:113-119.
  • 22. Ajayi AA, Ukponmwan OE. Possible evidence of angiotensin II and endogenous opioid modulation of novelty-induced rearing in the rat. Afr J Med Med Sci 1994; 23:287-290.
  • 23. Reavill C, Kettle A, Holland V, Riley G, Blackburn TP. Attenuation of haloperidol-induced catalepsy by a 5-HT2c receptor antagonist. Br J Pharmacol 1999; 126:572-574.
  • 24. Dong SM, Kim YG, Heo J, Ji MK, Cho JW, Kwak BS. YKP1447, a novel potential atypical antipsychotic agent. Korean J Physiol Pharmacol 2009;13:71-78.
  • 25. Amos S, Abbah J, Chindo B, Edmond I, Binda L, Adzu B, Buhari S, Odutola AA, Wambebe C, Gamaniel K. Neuropharmacological effects of the aqueous extract of Nauclea latifolia root bark in rats and mice. J Ethnopharmacol 2005; 97:53-57.
  • 26. Zisapel N, Nir I, Laudon M. Circadian variations in melatonin-binding sites in discrete areas of the male rat brain. FEBS Lett 1988; 232:172-176.
  • 27. Zisapel N, Egozi Y, Laudon M. Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Res 1982; 246:161-163.
  • 28. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Second Ed., Cambridge: Cambridge University Press, 2000.
  • 29. Muller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurtransmission. Neurotox Res 2006; 10:131-148.
  • 30. Rothermundt M, Arolt V, Bayer TA. Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 2001; 15:319-339.
  • 31. Allegri G, Costa CV, Bertazzo A, Biasiolo M, Ragazzi E. Enzyme activities of tryptophan metabolism along the kynurenine pathway in various species of animals. Farmaco 2003; 58:829-836.
  • 32. Stone TW. Neuropharmacolgy of quinolinic acid and kynurenic acids. Pharmacol Rev 1993; 45:309-379.
  • 33. Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol 1999; 375:87-100.
  • 34. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50:521-530.
  • 35. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M. Thecyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: result so fadouble-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11:680-684.
  • 36. Myint AM, Kim YK. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 2003; 61:519-525.
  • 37. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13:465-477.
  • 38. Sandyk R, Kay SR. Down regulation of 5-HT2 receptors: possible role of melatonin and significance for negative schizophrenia. Int J Neurosci 1991; 56:209-214.
  • 39. Uzbay IT. New pharmacological approaches to the treatment of schizophrenia. Turk Psikiyatri Derg 2009; 20:175-182. (Turkish)
  • 40. Schatzberg AF, Cole JO, DeBattista C. Manual of clinical pharmacology. Fourth ed., Washington, DC: American Psychiatric Publishing, Inc., 2003, 187-243.
Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi-Cover
  • ISSN: 1018-8681
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1984
  • Yayıncı: Kare Yayıncılık
Sayıdaki Diğer Makaleler

The impact of caregivers' expressed emotion and the patients' perception of expressed emotion on the positive and negative symptoms of patients with schizophrenia in a sample from Turkey

Gulbahar BASTUG, Nuray KARANCİ

The Interaction Between Attention Deficit Hyperactivity Disorder and Anxiety Symptoms

SEBLA GÖKÇE, Ayşe Burcu AYAZ, Ayşe ARMAN RODOPMAN, Esengul KAYAN

Drawing Attention to Addiction in Women by Evaluating Female Inpatients Hospitalized in MRSHH-AMATEM

Aslihan ESLEK YAPİCİ, Nevriye OZSAHİN, Ilhan ESLEK, Ahmet AYER

Uncommon Organic Psychosis: an Adolescent Case ofAnti-N-Methyl-D-Aspartate Receptor Encephalitis

Hamiyet İPEK, Caner MUTLU, Hafize Emine SONMEZ, Özden Şükran ÜNERİ

Burden and Burden-related Features in Caregivers of Schizophrenia Patients

Aslı ÖZLÜ, Mustafa YILDIZ, Tamer AKER

Bipolar Depression: An Orphan Syndrome?

Ross BALDESARINI

A Cause of Intractable Epilepsy: Bilateral Posterior Agyria-Pachygyria

Temel TOMBUL, Aysel MİLANLIOĞLU, Ömer Faruk ODABAŞ

The impact of caregivers' expressed emotion and the patients' perception of expressed emotion on the positive and negative symptoms of patients with schizophrenia in a sample from Turkey

GÜLBAHAR BAŞTUĞ, Nuray KARANCI

Eating Attitudes, Depression and Anxiety Levels of Patients with Hyperemesis Gravidarum Hospitalized in an Obstetrics and Gynecology Clinic

Ebru KENDER ERGİNBAS, Gökşen YÜKSEL, Can GER, ÜRÜN ÖZER ÇERİ

Morning Glory Syndrome and Autism: A Case Report

ALİ KARAYAĞMURLU, Cem GÖKÇEN, Celal VARAN